Ontology highlight
ABSTRACT:
SUBMITTER: Martin LP
PROVIDER: S-EPMC3494424 | biostudies-literature | 2012 Oct
REPOSITORIES: biostudies-literature
Martin L P LP Kozloff M F MF Herbst R S RS Samuel T A TA Kim S S Rosbrook B B Tortorici M M Chen Y Y Tarazi J J Olszanski A J AJ Rado T T Starr A A Cohen R B RB
British journal of cancer 20120920 8
<h4>Background</h4>Axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors, enhanced the efficacy of chemotherapy in human xenograft tumour models. This phase I study investigated the safety, tolerability, pharmacokinetics and antitumour activity of axitinib combined with chemotherapy.<h4>Methods</h4>A total of 42 patients with advanced solid tumours received a continuous axitinib starting dose of 5 mg twice daily (b.i.d.) plus paclitaxel (90 ...[more]